Anesiva culls jobs on mixed Adlea data
This article was originally published in Scrip
Executive Summary
Anesiva is cutting 85% of its workforce and will stop marketing its lead product following mixed Phase III trial results for its post-surgical pain candidate Adlea. The firm's headcount will fall to 15 employees who will solely concentrate on the Adlea programme.